Tag:
MorphoSys
Latest Headlines
Latest Headlines
GlaxoSmithKline grabs PhII rheumatoid arthritis drug in $579M MorphoSys deal
GSK is paying about $28 million of that upfront and will take over all further R&D and commercialization efforts. MorphoSys snags a double-digit royalty stream from any sales that might come along with up to $550 million in milestones.
MorphoSys zeroes in on partner for blockbuster hopeful against arthritis
New clinical data have bolstered MorphoSys CEO Simon Moroney's blockbuster hopes for the biotech's experimental antibody against rheumatoid arthritis (RA), and the chief executive is hunting for a partner to aid in developing the drug that he believes could generate north of $1 billion in annual sales, Reuters reported.
Roche stakes its claim as the leader in high-risk Alzheimer's R&D
That dark cloud you've been watching form around the late-stage Alzheimer's drug development field has come equipped with a bright silver lining for Roche.
MorphoSys unit, Pfizer ink Slonomics pact
German biotech MorphoSys has had a busy morning. It announced today that its subsidiary Sloning BioTechnology has signed a non-exclusive license and technology transfer agreement with pharma giant
Galapagos inks development pact with MorphoSys
Shares of Belgium's Galapagos surged on the news that it had partnered with Germany's MorphoSys AG to develop antibodies for bone and joint diseases. The two companies plan to jointly invest 30
Daiichi snares Germany's U3 in $235M acquisition
Daiichi Sankyo is buying Germany's U3 Pharma for $235 million in cash. The Japanese pharma company gains a developer that's been
ALSO NOTED: Salix gets approvable letter; Intermune drug hits the fast track; and much more...
> Should Fred Hassan ( photo ) give back his bonus? That's what Forbes is asking this week, saying that the
ALSO NOTED: Endo buys Novartis' Voltaren; Microbia, Forest produce positive Phase III data; and much more...
> Endo Pharmaceutical is buying Novartis' Voltaren gel for $85 million upfront and a one-time sales milestone of $25 million.
ALSO NOTED: Cephalon, NitroMed make cuts jobs; IonGate gains funds; and much more...
> Cephalon is cutting jobs as it restructures, shifting manufacturing work from Minnesota to Salt Lake City and relocating some R&D work from Salt Lake City to Minnesota.
